Myovant Sciences announces positive results from second phase 3 study
Myovant Sciences announced that LIBERTY 2, the second of two Phase 3 studies of once-daily relugolix combination therapy, met its primary efficacy endpoint and six key secondary endpoints in women with uterine fibroids. July 23, 2019